Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).

被引：3
作者：
Nokihara, Hiroshi
Katakami, Nobuyuki
Hida, Toyoaki
Imamura, Fumio
Sakai, Hiroshi
Atagi, Shinji
Nishio, Makoto
Helwig, Christoph
Achiwa, Hiroyuki
Tamura, Tomohide
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
[3] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[4] Osaka Med Ctr, Osaka, Japan
[5] Saitama Canc Ctr, Saitama, Japan
[6] Kinki Chuo Chest Med Ctr, Osaka, Japan
[7] Japanese Fdn Canc Res, Tokyo, Japan
[8] Merck KGaA, Darmstadt, Germany
[9] Merck Serono Co Ltd, Tokyo, Japan
[10] St Lukes Int Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3036
引用
收藏
页数：1
相关论文
共 50 条
[21]   Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer [J].
Makoto Sonobe ;
Ken-ichi Okubo ;
Satoshi Teramukai ;
Kazuhiro Yanagihara ;
Masaaki Sato ;
Toshihiko Sato ;
Fengshi Chen ;
Kiyoshi Sato ;
Takuji Fujinaga ;
Tsuyoshi Shoji ;
Mitsugu Omasa ;
Hiroaki Sakai ;
Ryo Miyahara ;
Toru Bando ;
Hiroshi Date .
Cancer Chemotherapy and Pharmacology, 2014, 74 :1199-1206
[22]   Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer [J].
Sonobe, Makoto ;
Okubo, Ken-ichi ;
Teramukai, Satoshi ;
Yanagihara, Kazuhiro ;
Sato, Masaaki ;
Sato, Toshihiko ;
Chen, Fengshi ;
Sato, Kiyoshi ;
Fujinaga, Takuji ;
Shoji, Tsuyoshi ;
Omasa, Mitsugu ;
Sakai, Hiroaki ;
Miyahara, Ryo ;
Bando, Toru ;
Date, Hiroshi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) :1199-1206
[23]   Phase II study of mitonafide in non-small cell lung cancer (NSCLC) [J].
Casado, A ;
Rosell, R ;
GarciaGomez, R ;
DiazRubio, E ;
PerezManga, G ;
Font, A ;
Benavides, A ;
Martin, M .
INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) :415-417
[24]   CONCURRENT CHEMORADIATION (CCHRT) FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY FROM THE GALICIAN LUNG CANCER GROUP [J].
Casal, Joaquin ;
Ponte, C. ;
Senin, C. ;
Campos, B. ;
Firvida, Xl ;
Carmona, M. ;
Hernandez, E. ;
Lopez, Md ;
Formoso, I. ;
Lazaro, M. ;
Vazquez, S. ;
Areses, Mc ;
Rodriguez, C. ;
Pena, C. ;
Villanueva, Mj .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S849-S849
[25]   PROGNOSTIC FACTORS IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER [J].
Boku, S. ;
Kasamatsu, Y. ;
Kida, T. ;
Kasamatsu, Y. .
ANNALS OF ONCOLOGY, 2013, 24
[26]   Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer [J].
Bradley, Jeffrey D. .
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) :853-855
[27]   Is durvalumab the solution for unresectable stage III non-small cell lung cancer? [J].
Duma, Narjust ;
Mansfield, Aaron S. .
TRANSLATIONAL CANCER RESEARCH, 2018, 7 :S89-S93
[28]   A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer [J].
Bartolomeo, Valentina ;
Cortiula, Francesco ;
Hendriks, Lizza E. L. ;
De Ruysscher, Dirk ;
Filippi, Andrea R. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05) :1455-1460
[29]   A randomized multicenter phase II study of concurrent pemetrexed and radiotherapy with induction or adjuvant cisplatin/pemetrexed in patients with unresectable stage III non-small cell lung cancer (NSCLC) [J].
Germonpre, Paul R. ;
Janssens, Annelies ;
Galdermans, Danny ;
Ortmanns, Paul ;
Deschepper, Koen ;
Devogelaere, Roger ;
De Droogh, Els ;
De Pooter, Christel ;
Goor, Chris .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) :S853-S853
[30]   Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer [J].
Vokes, EE ;
Crawford, J ;
Bogart, J ;
Socinski, MA ;
Clamon, G ;
Green, MR .
CLINICAL CANCER RESEARCH, 2005, 11 (13) :5045S-5050S
12345